# Golimumab

## Simponi inj 50mg/0.5mL

##### 臨採

| TAH Drug Code      | [**ISIM**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ISIM)                                                                                                                                                                                                                                                                         |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | In combination w/ methotrexate for the treatment of moderate to severe active RA. Alone or in combination w/ methotrexate for active psoriatic arthritis (PsA). Treatment of active ankylosing spondylitis (AS).                                                                                                                                 |
| Dosing             | SC, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis 50 mg once a month. Moderate to severe active ulcerative colitis( body weight<80 kg) 200 mg at week 0, then 100 mg at week 2, followed by 50-100 mg every 4 weeks.( body weight > or = 80kg) 200 mg at week 0, then 100 mg at week 2, followed by 100 mg every 4 weeks. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                    |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                    |
| Contraindications  | Canadian labeling: Hypersensitivity to golimumab, latex, or any other component of formulation or packaging; patients with severe infections (eg, sepsis, tuberculosis, opportunistic infections); moderate or severe heart failure (NYHA class III/IV)                                                                                          |
| Adverse Effects    | Serious infections, malignancies, autoimmune disorders & autoantibodies, inj site reactions, new onset & exacerbations of psoriasis, immunogenicity, upper resp tract infection, nasopharyngitis, sepsis, increased ALT & AST; HTN, bronchitis, dizziness, sinusitis, flu, pharyngitis, rhinitis, pyrexia, oral herpes, paraesthesia.            |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                           |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                    |

